QT-019C
Phase 1Cell therapy
QT-019C is one of 91 small molecule programs targeting Autoimmune Disease. It is currently in Phase 1.
2
Indications
3
Total Trials
3
Active Trials
90
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
74 competitors in Autoimmune Disease
#DrugCompanyPhaseTrials
1Atgam
NovartisPhase 2
Cytosar
TevaPhase 2
Rayos
RRoxane Laboratories
Phase 2
Vepesid
AAvyxa
Phase 2
Bicnu
MMelissa K Accordino
Phase 2
Alkeran
AApotex Inc.
Phase 2
Fludara
SanofiPhase 1
Rituxan
RochePhase 1
CAR-T Cell
PPersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 2
Anti-CD19 CAR-T Cells
TThe Children's Hospital of Zhejiang University School of Medicine
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Autoimmune Disease2 trials
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07315087·12 enrolled
Immune Thrombocytopenia1 trial
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia
Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT07416032·27 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for QT-019C. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- TTianjin Huanhu Hospital